# Frontier Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/frontier-biotechnologies

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.frontierbiotech.com
- Total disclosed funding: $43M
- Latest round: Series C (Jan 3, 2017)
- Investors on record: 3

## About

Founded in 2002 and based in Nanjing, China, Frontier Biotechnologies Inc. operates as an innovative drug developer that focuses on AIDS antiviral treatment and pain fields. In 2018, Frontier's product - Aibo Weitai was approved for listing. It listed on the Shanghai Stock Exchange in October 2020 and the stock code is 688221. Asymchem Laboratories(Tianjin)Co.,Ltd. has become the strategic partner of the company in July 2022. The production base located in Nanjing, Sichuan and Shandong, Nanjing's production base covering an area of 65 Mu.

Its products include pipeline and Aikening TM. Pipeline includes FB1002, FB2001, FB3001 and FB6001. FB1002 is a novel broad-spectrum HIV neutralizing antibody. FB3001 is a new transdermal patch for musculoskeletal pain. Frontier Biotechnologies develops long acting polypeptide technology platform and new transdermal patch preparation technology platform.

## Funding rounds

- Series C, Jan 3, 2017, $43M — Efung Capital, Huaxin Century Investment Group, Shenzhen Capital Real Estate Fund
- Series B, Jun 1, 2016 — Efung Capital

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B, Series C
- Huaxin Century Investment Group — Series C
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C